

Application Serial No.: 09/740,191  
Attorney Docket No.: ARC2556N1

Page 2

**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims**

1 – 11. (canceled)

12. (currently amended) A sustained-release dosage form for the delivery of a progestogenic steroid, the dosage form comprising:

a capsule;

a self-emulsifying drug formulation contained within a first portion of the capsule, wherein the self-emulsifying drug formulation comprises a progestogenic steroid;

an expandable layer contained within a second portion of the capsule, wherein the expandable layer is positioned such that the self-emulsifying drug formulation can be expelled from the capsule upon expansion of the expandable layer; and

a semipermeable membrane formed over at least a portion of an outer surface of the capsule.

13. (previously presented) The dosage form of claim 12, wherein the expandable layer comprises an osmotic hydrogel, an osmotically effective solute, and a hydroxyalkylcellulose.

14. (previously presented) The dosage form of claim 12, further comprising an exit orifice that is formed or formable within the semipermeable membrane.

15. (previously presented) The dosage form of claim 12, wherein the semipermeable membrane comprises a cellulose acetate and a polyethylene glycol.

16. (canceled)

17. (currently amended) The dosage form of claim 12, wherein the self-emulsifying drug formulation comprises a surfactant selected from the group consisting of polyoxyethylenated castor oil comprising 9 moles to 52 moles of ethylene oxide, polyoxyethylenated sorbitan monopalmitate comprising 20 moles of ethylene oxide, polyoxyethylenated sorbitan monostearate comprising 20 moles of ethylene oxide, polyoxyethylenated sorbitan monostearate comprising 4 moles of ethylene oxide, polyoxyethylenated sorbitan tristearate comprising 20 moles of ethylene oxide, ~~polyoxyethylenated sorbitan monostearate comprising 20 moles of ethylene oxide~~, polyoxyethylenated sorbitan trioleate comprising 20 moles of ethylene oxide, polyoxyethylenated stearic acid comprising 8 moles of ethylene oxide, polyoxyethylene lauryl ether, polyoxyethylenated stearic acid comprising 40 moles to 50 moles of ethylene oxide, polyoxyethylenated stearic acid comprising 50 moles of ethylene oxide, polyoxyethylenated stearyl alcohol comprising 2 moles of ethylene oxide, and polyoxyethylenated oleyl alcohol comprising 2 moles of ethylene oxide.

18. (previously presented) The dosage form of claim 12, wherein the self-emulsifying drug formulation comprises an oil selected from the group consisting of a vegetable, mineral, animal and marine oil, an ester of an unsaturated fatty acid, a monoglyceride, a diglyceride, a triglyceride, an acetylated glyceride, olein, palmitin, stearin, lauric acid hexylester, oleic acid, oleylester, glycolyzed ethoxylated glycerides of oils, fatty acids comprising 13 molecules of ethyleneoxide, and oleic acid decylester.

19-23. (canceled)

24. (previously presented) The dosage form of claim 12, wherein the semipermeable membrane comprises a thermoplastic polymer composition having a softening point of 40°C to 180°C.